Literature DB >> 9131723

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

A Meyer-Lindenberg1, H Gruppe, U Bauer, S Lis, S Krieger, B Gallhofer.   

Abstract

Clinical interest in the so-called atypical antipsychotics currently focuses on the possibility of improving the negative symptoms of schizophrenia and the cognitive dysfunction associated with the disease. While clozapine has been shown to be effective in this respect, no data are available on zotepine. We report on a double-blind randomized study designed to evaluate the impact of zotepine and clozapine on cognitive dysfunction in schizophrenia. Cognitive function was operationalized by a maze test in which patients traversed computer-displayed mazes of increasing complexity. Passage time, route, and motor errors were evaluated. 25 schizophrenic (DSM-IIIR) patients were included in each group. After washout, they were randomized on zotepine or clozapine and given up to 450 mg of substance each. Patients were followed for six weeks and evaluated weekly. We report on a subsample of 26 patients matched for baseline BPRS, SANS, and age. 13 matched healthy persons were recruited as controls. ANOVA with group and course over time as factors was used for analysis. Both clozapine and zotepine achieved a highly significant decrease in overall symptoms (BPRS) and negative symptoms (SANS). Zotepine and clozapine were equally effective. In the maze tests, motor errors in simple mazes were stable over time and differentiated schizophrenics from controls as a "trait" marker. In passage time and maze route, schizophrenics performed worse than controls. An improvement by medication was evident in both medication groups, but was more pronounced in the zotepine-treated group. The study confirms previous results on the efficacy of clozapine and zotepine in treating negative symptoms of schizophrenia. The data presented show for the first time that zotepine is efficacious in improving cognitive dysfunction, confirming this substance's value as an atypical antipsychotic.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131723     DOI: 10.1055/s-2007-979481

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  15 in total

Review 1.  Zotepine versus other atypical antipsychotics for schizophrenia.

Authors:  Selvizhi Subramanian; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Werner Kissling; Stefan Leucht; Katja Komossa
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  Treating cognitive dysfunction in patients with schizophrenia.

Authors:  C A Galletly; C R Clark; A C MacFarlane
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 3.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Zotepine for schizophrenia.

Authors:  P DeSilva; M Fenton; J Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

5.  Chronic, but not acute, dosing of antipsychotic drugs alters neurotensin binding in rat brain regions.

Authors:  P E Holtom; P L Needham; G W Bennett; S Aspley
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

6.  Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.

Authors:  Tonmoy Sharma; Catherine Hughes; William Soni; Veena Kumari
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

7.  Zotepine for behavioural and psychological symptoms in dementia: an open-label study.

Authors:  Michael K Rainer; Hermann A M Mucke; Christine Krüger-Rainer; Manfred Haushofer; Sigfried Kasper
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex.

Authors:  S Yamamura; K Ohoyama; T Hamaguchi; M Nakagawa; D Suzuki; T Matsumoto; E Motomura; H Tanii; T Shiroyama; M Okada
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

9.  [Atypical antipsychotics in therapy refractory schizophrenia].

Authors:  I Schäfer; M Lambert; D Naber
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

10.  Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Authors:  Pierre Chue
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.